Treatment with vildagliptin at a dose that elevated serum GLP-1 without normalization of plasma glucose level reduced acute mortality after MI in a rat model of T2DM to the level in non-diabetic controls. The gene discussed is GCG; the disease is type 2 diabetes mellitus.